Characteristics of PsO or PsA patients at the time of index date, overall and by drug class
| All (n=11 560) | IL-17 (n=2148) | IL-12/23 (n=2882) | TNF (n=6530) | |
| Age | 46 (12) | 48 (11) | 46 (12) | 46 (12) |
| Male | 6107 (53%) | 1141 (53%) | 1569 (54%) | 3397 (52%) |
| Household income | ||||
| <$40 000 | 1372 (12%) | 277 (13%) | 333 (12%) | 762 (12%) |
| $40 000–$74 999 | 2818 (24%) | 477 (22%) | 678 (24%) | 1663 (26%) |
| $75 000–$124 999 | 3694 (32%) | 682 (32%) | 922 (32%) | 2090 (32%) |
| $125 000–$199 999 | 2137 (19%) | 415 (19%) | 529 (18%) | 1193 (18%) |
| >$200 000 | 1539 (13%) | 297 (14%) | 420 (15%) | 822 (13%) |
| Diagnosis | ||||
| PsO only | 6043 (52%) | 1204 (56%) | 1994 (69%) | 2846 (44%) |
| PsA only | 1869 (16%) | 245 (11%) | 239 (8%) | 1388 (21%) |
| PsO and PsA | 3648 (32%) | 699 (33%) | 650 (23%) | 2299 (35%) |
| Charlson Comorbidity Index score | ||||
| 0 | 8248 (71%) | 1429 (67%) | 2158 (75%) | 4661 (71%) |
| 1 | 2192 (19%) | 477 (22%) | 468 (16%) | 1247 (19%) |
| 2 or more | 1120 (10%) | 242 (11%) | 256 (9%) | 622 (10%) |
| Number of previous biologics | ||||
| 0 | 5995 (52%) | 332 (16%) | 1344 (47%) | 4319 (66%) |
| 1 | 3614 (31%) | 817 (38%) | 1121 (39%) | 1676 (26%) |
| 2 or more | 1951 (17%) | 999 (46%) | 417 (14%) | 535 (8%) |
| DMARDs in past 6 months | 3115 (27%) | 519 (24%) | 619 (22%) | 1977 (30%) |
| Methotrexate | 2032 (18%) | 251 (12%) | 345 (12%) | 1436 (22%) |
| Sulfasalazine | 249 (2%) | 22 (1%) | 28 (1%) | 199 (3%) |
| Apremilast | 796 (7%) | 228 (11%) | 240 (8%) | 328 (5%) |
| Other | 369 (3%) | 77 (4%) | 81 (3%) | 211 (3%) |
| Oral steroids in past 6 months, % | 3989 (35%) | 732 (34%) | 891 (31%) | 2366 (36%) |
| NSAIDs prescribed in past 6 months | 1594 (14%) | 278 (13%) | 262 (9%) | 1054 (16%) |
| Phototherapy in past 6 months | 261 (2%) | 39 (2%) | 93 (3%) | 129 (2%) |
Continuous variables are presented as mean (SD), and categorical variables are presented as counts (percentages).
DMARD, disease-modifying antirheumatic drugs; IL, interleukin; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis; PsO, psoriasis.